WO2015099364A1 - 아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 - Google Patents
아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 Download PDFInfo
- Publication number
- WO2015099364A1 WO2015099364A1 PCT/KR2014/012602 KR2014012602W WO2015099364A1 WO 2015099364 A1 WO2015099364 A1 WO 2015099364A1 KR 2014012602 W KR2014012602 W KR 2014012602W WO 2015099364 A1 WO2015099364 A1 WO 2015099364A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sustained
- release
- pharmaceutical composition
- acebrophylline
- hydrophobic
- Prior art date
Links
- 238000013268 sustained release Methods 0.000 title claims abstract description 75
- 239000012730 sustained-release form Substances 0.000 title claims abstract description 75
- IPUHJDQWESJTGD-PFWPSKEQSA-N Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O.Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 Chemical compound Cn1c2ncn(CC(O)=O)c2c(=O)n(C)c1=O.Nc1c(Br)cc(Br)cc1CN[C@H]1CC[C@H](O)CC1 IPUHJDQWESJTGD-PFWPSKEQSA-N 0.000 title claims abstract description 62
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 47
- 230000002209 hydrophobic effect Effects 0.000 title claims abstract description 40
- 239000000203 mixture Substances 0.000 claims description 50
- 238000004090 dissolution Methods 0.000 claims description 34
- 238000000034 method Methods 0.000 claims description 28
- 210000004369 blood Anatomy 0.000 claims description 25
- 239000008280 blood Substances 0.000 claims description 25
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 23
- 229960005174 ambroxol Drugs 0.000 claims description 23
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 17
- 229920000193 polymethacrylate Polymers 0.000 claims description 11
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 10
- 239000001993 wax Substances 0.000 claims description 10
- 239000001856 Ethyl cellulose Substances 0.000 claims description 8
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 8
- ZFOZVQLOBQUTQQ-UHFFFAOYSA-N Tributyl citrate Chemical compound CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC ZFOZVQLOBQUTQQ-UHFFFAOYSA-N 0.000 claims description 8
- 229920001249 ethyl cellulose Polymers 0.000 claims description 8
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 8
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 7
- 229960004667 ethyl cellulose Drugs 0.000 claims description 7
- 238000002156 mixing Methods 0.000 claims description 7
- 206010006451 bronchitis Diseases 0.000 claims description 6
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 claims description 5
- 229920001800 Shellac Polymers 0.000 claims description 5
- 229920002494 Zein Polymers 0.000 claims description 5
- 235000013869 carnauba wax Nutrition 0.000 claims description 5
- 239000004203 carnauba wax Substances 0.000 claims description 5
- 229940049654 glyceryl behenate Drugs 0.000 claims description 5
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 5
- -1 polyoxyglycerides Natural products 0.000 claims description 5
- 239000004208 shellac Substances 0.000 claims description 5
- 229940113147 shellac Drugs 0.000 claims description 5
- 235000013874 shellac Nutrition 0.000 claims description 5
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 239000005019 zein Substances 0.000 claims description 5
- 229940093612 zein Drugs 0.000 claims description 5
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 4
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 4
- QZCLKYGREBVARF-UHFFFAOYSA-N Acetyl tributyl citrate Chemical group CCCCOC(=O)CC(C(=O)OCCCC)(OC(C)=O)CC(=O)OCCCC QZCLKYGREBVARF-UHFFFAOYSA-N 0.000 claims description 4
- PYGXAGIECVVIOZ-UHFFFAOYSA-N Dibutyl decanedioate Chemical compound CCCCOC(=O)CCCCCCCCC(=O)OCCCC PYGXAGIECVVIOZ-UHFFFAOYSA-N 0.000 claims description 4
- 235000021355 Stearic acid Nutrition 0.000 claims description 4
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 claims description 4
- 239000004359 castor oil Substances 0.000 claims description 4
- 235000019438 castor oil Nutrition 0.000 claims description 4
- 229920002301 cellulose acetate Polymers 0.000 claims description 4
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 4
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 claims description 4
- FETSQPAGYOVAQU-UHFFFAOYSA-N glyceryl palmitostearate Chemical compound OCC(O)CO.CCCCCCCCCCCCCCCC(O)=O.CCCCCCCCCCCCCCCCCC(O)=O FETSQPAGYOVAQU-UHFFFAOYSA-N 0.000 claims description 4
- 229940046813 glyceryl palmitostearate Drugs 0.000 claims description 4
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 4
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 4
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 4
- 239000008117 stearic acid Substances 0.000 claims description 4
- 206010006458 Bronchitis chronic Diseases 0.000 claims description 3
- 229920000623 Cellulose acetate phthalate Polymers 0.000 claims description 3
- 208000014085 Chronic respiratory disease Diseases 0.000 claims description 3
- 208000006673 asthma Diseases 0.000 claims description 3
- 229940081734 cellulose acetate phthalate Drugs 0.000 claims description 3
- 208000007451 chronic bronchitis Diseases 0.000 claims description 3
- 239000008172 hydrogenated vegetable oil Substances 0.000 claims description 3
- 208000030603 inherited susceptibility to asthma Diseases 0.000 claims description 3
- XUGNVMKQXJXZCD-UHFFFAOYSA-N isopropyl palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC(C)C XUGNVMKQXJXZCD-UHFFFAOYSA-N 0.000 claims description 3
- 230000002265 prevention Effects 0.000 claims description 3
- 208000023504 respiratory system disease Diseases 0.000 claims description 3
- 201000009890 sinusitis Diseases 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 229940045860 white wax Drugs 0.000 claims description 3
- 230000001154 acute effect Effects 0.000 claims description 2
- RAGVGXLZTQDOKB-UHFFFAOYSA-N 2-hydroxypropane-1,2,3-tricarboxylic acid;tributyl 2-hydroxypropane-1,2,3-tricarboxylate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCCOC(=O)CC(O)(C(=O)OCCCC)CC(=O)OCCCC RAGVGXLZTQDOKB-UHFFFAOYSA-N 0.000 claims 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims 1
- 229940049964 oleate Drugs 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 206010039083 rhinitis Diseases 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 238000013265 extended release Methods 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 22
- 229940079593 drug Drugs 0.000 description 21
- 239000003814 drug Substances 0.000 description 21
- 230000000052 comparative effect Effects 0.000 description 17
- 239000003826 tablet Substances 0.000 description 17
- 239000011248 coating agent Substances 0.000 description 16
- 239000002775 capsule Substances 0.000 description 13
- 239000008187 granular material Substances 0.000 description 13
- 238000000576 coating method Methods 0.000 description 12
- 239000000243 solution Substances 0.000 description 12
- 238000010828 elution Methods 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000000694 effects Effects 0.000 description 10
- 230000001225 therapeutic effect Effects 0.000 description 10
- 239000000654 additive Substances 0.000 description 8
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- ZFXYFBGIUFBOJW-UHFFFAOYSA-N Theophylline Natural products O=C1N(C)C(=O)N(C)C2=C1NC=N2 ZFXYFBGIUFBOJW-UHFFFAOYSA-N 0.000 description 6
- 238000001727 in vivo Methods 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- JIGUQPWFLRLWPJ-UHFFFAOYSA-N Ethyl acrylate Chemical compound CCOC(=O)C=C JIGUQPWFLRLWPJ-UHFFFAOYSA-N 0.000 description 5
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 5
- 238000007922 dissolution test Methods 0.000 description 5
- 125000005397 methacrylic acid ester group Chemical group 0.000 description 5
- PNJWIWWMYCMZRO-UHFFFAOYSA-N pent‐4‐en‐2‐one Natural products CC(=O)CC=C PNJWIWWMYCMZRO-UHFFFAOYSA-N 0.000 description 5
- 125000001453 quaternary ammonium group Chemical group 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 239000002253 acid Substances 0.000 description 4
- 239000011230 binding agent Substances 0.000 description 4
- 229920002678 cellulose Polymers 0.000 description 4
- 239000001913 cellulose Substances 0.000 description 4
- 235000010980 cellulose Nutrition 0.000 description 4
- 229920001600 hydrophobic polymer Polymers 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000314 lubricant Substances 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 4
- 210000002966 serum Anatomy 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229960000278 theophylline Drugs 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 239000003085 diluting agent Substances 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000007789 gas Substances 0.000 description 3
- 150000002617 leukotrienes Chemical class 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 3
- 150000003180 prostaglandins Chemical class 0.000 description 3
- 230000002459 sustained effect Effects 0.000 description 3
- 239000000454 talc Substances 0.000 description 3
- 229910052623 talc Inorganic materials 0.000 description 3
- 235000012222 talc Nutrition 0.000 description 3
- 239000012178 vegetable wax Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- ZAMLGGRVTAXBHI-UHFFFAOYSA-N 3-(4-bromophenyl)-3-[(2-methylpropan-2-yl)oxycarbonylamino]propanoic acid Chemical compound CC(C)(C)OC(=O)NC(CC(O)=O)C1=CC=C(Br)C=C1 ZAMLGGRVTAXBHI-UHFFFAOYSA-N 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 201000008283 Atrophic Rhinitis Diseases 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerol Natural products OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 239000004372 Polyvinyl alcohol Substances 0.000 description 2
- 206010039088 Rhinitis atrophic Diseases 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 229940081735 acetylcellulose Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000002844 continuous effect Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000004807 desolvation Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 2
- 229910000397 disodium phosphate Inorganic materials 0.000 description 2
- 235000019800 disodium phosphate Nutrition 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 239000003480 eluent Substances 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 229940081618 glyceryl monobehenate Drugs 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 2
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 239000011159 matrix material Substances 0.000 description 2
- 239000013563 matrix tablet Substances 0.000 description 2
- VNWKTOKETHGBQD-UHFFFAOYSA-N methane Chemical compound C VNWKTOKETHGBQD-UHFFFAOYSA-N 0.000 description 2
- 229940016286 microcrystalline cellulose Drugs 0.000 description 2
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 2
- 239000008108 microcrystalline cellulose Substances 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 229920002451 polyvinyl alcohol Polymers 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229960002639 sildenafil citrate Drugs 0.000 description 2
- DEIYFTQMQPDXOT-UHFFFAOYSA-N sildenafil citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.CCCC1=NN(C)C(C(N2)=O)=C1N=C2C(C(=CC=1)OCC)=CC=1S(=O)(=O)N1CCN(C)CC1 DEIYFTQMQPDXOT-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 239000012085 test solution Substances 0.000 description 2
- 238000005550 wet granulation Methods 0.000 description 2
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- ATRRKUHOCOJYRX-UHFFFAOYSA-N Ammonium bicarbonate Chemical compound [NH4+].OC([O-])=O ATRRKUHOCOJYRX-UHFFFAOYSA-N 0.000 description 1
- 208000009079 Bronchial Spasm Diseases 0.000 description 1
- 208000014181 Bronchial disease Diseases 0.000 description 1
- 206010006482 Bronchospasm Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000195493 Cryptophyta Species 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- 229920003159 Eudragit® RS 100 Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000721701 Lynx Species 0.000 description 1
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 102000015439 Phospholipases Human genes 0.000 description 1
- 108010064785 Phospholipases Proteins 0.000 description 1
- 206010036790 Productive cough Diseases 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 1
- 229920013820 alkyl cellulose Polymers 0.000 description 1
- 239000001099 ammonium carbonate Substances 0.000 description 1
- 235000012501 ammonium carbonate Nutrition 0.000 description 1
- 230000000181 anti-adherent effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000036765 blood level Effects 0.000 description 1
- 230000010083 bronchial hyperresponsiveness Effects 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- HUSUHZRVLBSGBO-UHFFFAOYSA-L calcium;dihydrogen phosphate;hydroxide Chemical compound O.[Ca+2].OP([O-])([O-])=O HUSUHZRVLBSGBO-UHFFFAOYSA-L 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000004581 coalescence Methods 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- 238000000748 compression moulding Methods 0.000 description 1
- 229920001531 copovidone Polymers 0.000 description 1
- HPXRVTGHNJAIIH-UHFFFAOYSA-N cyclohexanol Chemical compound OC1CCCCC1 HPXRVTGHNJAIIH-UHFFFAOYSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 229940031954 dibutyl sebacate Drugs 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 238000007907 direct compression Methods 0.000 description 1
- 238000007908 dry granulation Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000007721 medicinal effect Effects 0.000 description 1
- 238000007909 melt granulation Methods 0.000 description 1
- 229920003145 methacrylic acid copolymer Polymers 0.000 description 1
- 239000011259 mixed solution Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 229920001206 natural gum Polymers 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 229910000498 pewter Inorganic materials 0.000 description 1
- 239000010957 pewter Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000223 polyglycerol Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 235000019422 polyvinyl alcohol Nutrition 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 238000007873 sieving Methods 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000007939 sustained release tablet Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- XOOUIPVCVHRTMJ-UHFFFAOYSA-L zinc stearate Chemical compound [Zn+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O XOOUIPVCVHRTMJ-UHFFFAOYSA-L 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
Definitions
- Sustained-release pharmaceutical composition comprising acebrophylline and hydrophobic sustained-release agent
- the present invention relates to a sustained release pharmaceutical composition
- a sustained release pharmaceutical composition comprising acebrophylline and a hydrophobic sustained release agent.
- Acebrophylline (acebrophyl l ine) is a compound synthesized by ambroxol (ambroxol) with 7- theophylline (sal theophyl l ine), a salt consisting of an acid and a base. It is isolated and metabolized into Broxol and B- ⁇ Theophylline. Acebrophylline selectively acts on bronchial and lung tissues to inhibit the activity of phosphol ipase in the bronchoalveolar algae, and elevates the alveolar surface action, resulting in an expectorant action.
- LTs leukotrienes
- PGs prostaglandins
- Authorized acebrophylline formulations in the Republic of Korea are, for example, brand name sulfolase (modern drug), to be taken lOOmg twice a day, once a day or three times a day ( Compared with the drug taken before and after the meal, there is a problem that the point of taking is unclear, the patient's medication rate is decreased, and the dosing time (interval) is not constant, so that the desired therapeutic effect may not be obtained.
- sustained-release drugs that can exhibit continuous effects.However, if only continuous effects occur without rapid onset of effect, if rapid expression is required, such as respiratory disease, patients cannot expect rapid effects after taking them.
- acebrophylline Discomfort increases, and the desired therapeutic effect cannot be expected as compared with a commercially available formulation. Therefore, in order to compensate for this, it is necessary to develop an acebrophylline formulation that has both a fast-acting effect that can rapidly reach effective blood levels after administration and a sustained-effect characteristic that can keep the drug for a long time. Accordingly, the present inventors have studied to develop an acebrophylline formulation having both immediate release characteristics capable of expressing drug efficacy by rapidly reaching an effective blood concentration after administration and sustained release characteristics capable of maintaining long-acting effects. In addition to maintaining drug expression and sustained therapeutic effects, acebrophylline with 200 mg of acebrophylline taken twice a day for 200 mg once a day is developed to develop acebrophylline preparations with increased convenience. The present invention was completed.
- It is an object of the present invention to provide a pharmaceutical composition comprising acebrophylline having both rapid efficacy and sustainability and ease of taking, including acebrophylline.
- Another object of the present invention is to provide a method for imparting early immediate and late sustained release to acebrophylline pharmaceutical compositions.
- the present invention relates to a sustained release pharmaceutical composition
- a sustained release pharmaceutical composition comprising acebrophylline and hydrophobic sustained release base.
- the preparation prepared according to the present invention is superior to the initial dissolution rate than the preparation including the immediate release layer can be expected a fast therapeutic effect (experimental Example 1), because taking once a day alone can show a similar level of blood acebrophylline when taken twice a day (Experimental Examples 2 to 4), confirming that it is possible to increase the ease of taking and to expect an improved therapeutic effect.
- the present invention was completed.
- acebrophylline-containing pharmaceutical composition of the present invention contains a hydrophobic sustained release base including acebrophylline as an active ingredient, but exhibits a rapid dissolution rate and therefore has both fast action and sustainability.
- acebrophylline is a compound synthesized by the chloride of ambroxol with 7—theophylline (ambr 0X01 [tr ans-4-2-am i no-3, 5 ⁇ di br omobenzy 1] am i no cyc lohexanol ) wi th theophyl 1 ine-7-acet ic acid [l, 3 dimethylxanthine ⁇ 7— acet ic acid]).
- acebrophylline When acebrophylline is orally administered, it is metabolized and separated into ambroxol and gtheophylline, selectively acting on lung tissue, showing expectoration, and also inhibiting the production of leukotriene and prostaglandin. It can be used for the prevention or treatment of diseases, chronic respiratory diseases, acute bronchitis, chronic bronchitis, bronchial asthma, sinusitis or dry rhinitis.
- the present invention achieves rapid drug expression and sustained drug maintenance of acebrophylline, 1 selected from the group consisting of acute respiratory disease, chronic respiratory disease, acute bronchitis, chronic bronchitis bronchial asthma, sinusitis and dry rhinitis It can be used for the prevention or treatment of more than one disease.
- the content of acebrophylline included in the composition of the present invention can be easily determined by those skilled in the art according to the age, sex, disease severity, weight, etc. of the patient, but preferably may be included in an amount of 20 to 250 mg in total. More preferably 200 mg in total. Including less than 20 mg of acebrophylline does not exhibit the intended effect, and if it contains more than 250 mg may have side effects due to excessive pharmacological action and the mass of the composition itself increases, making it difficult to administer It is undesirable because of the problem of not being useful as a pharmaceutical composition.
- the hydrophobic sustained-release base material is a hydrophobic substance, and means a substance used to release a drug for a long time. Hydrophobicity is a property that cannot be mixed with water molecules, and since hydrophobic materials are generally nonpolar, they are well soluble in nonpolar solvents.
- Hydrophobic sustained-release bases include, but are not limited to, for example, cellulose-based hydrophobic polymers such as cel lulose acetate, eel lulose acetate phthalate and ethylcell. Ethylcel lulose], vegetable waxes (lead) [eg, Carnauba wax], glyceryl-based hydrophobic substances such as glycerin monostearate, glyceryl monooleate, glyceryl palmitostearate, polyglycerol Oxyglycerides and glyceryl behenate], vegetable oils (eg hydrogenated castor oil, hydrogenated vegetable oil type I), hydrophobic fatty acids [eg stearic acid] Acid and isopropyl palmitate], acetyltributyl citrate, tributyl citrate, white wax, yellow wax, zein ( zein, acetyl alcohol, acetyl esters wax, dibutyl sebacate
- the polymethacrylate is a polyalkyl methacrylate, specifically a copolymer of methacrylic acid ester having ethyl acrylate, methyl methacrylate and quaternary ammonium group, more specifically It is a co-polymer of ethyl acrylate, methyl methacrylate, and methacrylic acid ester which has quaternary ammonium group.
- polymethacrylates used in the present invention include Eudragit RS100, RS PO, RS 30D, RL100, RL PO, RL 30D, NE30D, NE40D, which are commercially available as polymethylmethacrylate copolymers. It is selected from the group consisting of FS30D and NM30D, but is not limited thereto.
- suitable hydrophobic sustained-release bases in the present invention are cellulose-based hydrophobic polymers (illustrated in Example 1, even more specifically d-C 5 alkyl cellulose, even more specifically ethylcellulose. ), Vegetable waxes (illustrated in Example 2, more specifically carnauba wax), glyceryl-based hydrophobic materials (illustrated in Example 3, more specifically the binding of C 14 -C 22 fatty acids to glycerol Glycerides, even more specifically glyceryl behenate), or polymethacrylate (illustrated in Example 4, more than Specifically, it is a copolymer of ethyl acrylate, methyl methacrylate and methacrylic acid ester having a quaternary ammonium group, and even more specifically the air of ethyl acrylate, methyl methacrylate and methacrylic acid ester having a quaternary ammonium group. Coalescence).
- the hydrophobic sustained-release base suitable in the present invention is a cellulose-based hydrophobic polymer or vegetable wax, even more specifically a cellulose-based hydrophobic polymer, most specifically ethyl cellulose.
- the hydrophobic base is not limited thereto, and the preferred content of the hydrophobic base is 10-50% by weight (more preferably, 15-40% by weight) based on the total weight of the unit dosage form. It releases more than 80% of the active ingredient in 6 hours, so that the drug can be delivered by only one administration on a daily basis. If it is less than the content, it is insufficient to achieve the same effect. This is undesirable because the overall weight of the formulation may be too large to cause discomfort.
- composition of the present invention may further comprise a coating base.
- a coating base examples thereof include at least one selected from the group consisting of hydroxypropyl methyl cellulose, polyvinyl alcohol, polypropylene glycol, acrylic acid polymer, polymethacrylate copolymer, polyethylene glycol polyvinylacetate, and mixtures thereof. May be, but is not limited thereto.
- composition may further include a pharmaceutically acceptable additive, and can be used a general additive that can improve the manufacture, appearance, compression, etc. of the drug within the range that does not impair the biological activity and properties of the drug. have.
- a pharmaceutically acceptable additive can be used a general additive that can improve the manufacture, appearance, compression, etc. of the drug within the range that does not impair the biological activity and properties of the drug. have.
- the specific content can be determined by standard pharmaceutical practices, as well as solubility and chemical properties of the active ingredient, the route of administration chosen.
- pharmaceutically acceptable additives include excipients, diluents, binders, lubricants, preservatives, stabilizers, anti-adhesives, glidants or colorants commonly used in the pharmaceutical field.
- starch microcrystalline cellulose, lactose, glucose, manny, dicalcium phosphate, and the like can be used as a diluent, and as a binder
- Polyvinylpyrrolidone derivatives such as hydroxypropyl cellulose, polyethylene glycol, polyvinylpyrrolidone, polyvinyl alcohol, copovidone, natural gums, synthetic gums, gelatin and the like can be used.
- Anhydrous silicic acid, talc, magnesium stearate, calcium stearate, zinc stearate, sodium stearyl fumarate, and the like may be used, but is not limited thereto.
- various additives such as antioxidants, colorants, flavors, preservatives, taste blockers, and the like, may be used in a conventional range of dosages by the choice of those skilled in the art.
- the pharmaceutical composition of the present invention has a dissolution rate of acebrophylline at 1 time after dissolution is 20-52% by weight (more specifically, SO-SO% by weight, even more specifically 30-50% by weight) %), And the dissolution rate of acebrophylline at the 6 hour time point is 75-100% by weight (more specifically, 80-100% by weight, more specifically 85-100% by weight). Accordingly, when the pharmaceutical composition is administered in the body, for example, the drug may exhibit desirable efficacy even under a reduced number of doses once a day. Therefore, it is possible to improve the ease of taking the patient using the pharmaceutical composition.
- the term "dissolution rate" is used at 500 mL of pH 1.2 eluate (the first solution of the Korean Pharmacopoeia Dissolution Test Method) using the paddle method of the Korean Pharmacopia No. 2 Elution test was started at 37 ° C 0.5 ° C and 50rpm, and when the elution test was started for 2 hours, 400 mL of test solution 2 (0.235 M anhydrous sodium hydrogen phosphate (Na 2 HP0 4 anhydrous)) was carefully added to the pH 1.2 eluent. This means that pH 6.8 is prepared and the dissolution test is performed continuously.
- the first solution was prepared by dissolving 7.0 mL of hydrochloric acid and water in 2.0 g of sodium chloride to make 1000 mL.
- the solution 2 was prepared in 250 mL of 0.2 mol / L potassium dihydrogen phosphate solution and 118 mL of 0.2 mol / L sodium hydroxide solution. And water to make 100 mL to prepare.
- the pharmaceutical composition of the present invention is not limited thereto, but may preferably be formulated in a dosage form suitable for oral administration, preferably in the form of a solid oral dosage form in consideration of the productivity of the producer and the convenience and portability of the patient. It may be provided as.
- the solid oral preparation is, for example, single stop 1, It may be a multilayer tablet, a nucleated tablet, a coated tablet or a capsule, such as a double tablet and a triple tablet, but is not limited thereto.
- there may be a single matrix sustained release tablet comprising an active ingredient comprising acebrophylline or a salt thereof and a hydrophobic sustained release base, additives, and coating base for controlling the dissolution of the active ingredient.
- the composition of the invention is provided in the form of a single matrix tablet.
- the composition of the invention has both immediate release and sustained release.
- rapid release as used to refer to a composition of the present invention refers to an initial after administration to a human body (eg, 2-4.5 hours after administration, 2-4 hours, 2.5- Drug release at 4 hours or 3-4 hours).
- the composition of the present invention has both immediate release characteristics capable of rapidly reaching an effective blood concentration after administration (eg, oral administration) and expressing the efficacy, and sustained release characteristics that can maintain the efficacy for a long time.
- the composition of the present invention is a 2-4.5 hour time point after oral administration once a day to the human body (more specifically, 2-4 hours, 2.5-4 hours or 3-4 hours
- the maximum blood concentration of Ambtoxol is shown in immediate release, followed by sustained release.
- the composition of the present invention when the human body orally administered 200 mg acebrophylline once a day, the maximum blood concentration of ambroxol is 90-250 ng / mL (more specifically, 100-250 ng / mL, 150-250 ng / mL, 200-250 ng / mL, 100-220 ng / mL, 150-220 ng / mL or 200-220 ng / mL).
- the composition of the present invention AUC ( 0 -36 hr) value for ambroxol in the blood is 1600-2 when orally administered 200 mg acebrophylline once a day to the human body , 700 ng-hr / mL.
- AUC ( 0-36 hr) value means the AUC value when measuring the blood ammoxol concentration for 36 hours after oral administration.
- the specific form and dosage of administration of the formulations of the present invention may be selected by the attending physician, depending on the characteristics of the patient, in particular age, weight, lifestyle, level of symptoms, and, in some cases, preferably Acebrophylline It may be prepared to take 200 mg once daily.
- each of the formulation forms possible in the present invention can be obtained by methods commonly known to the diabetic. For example, it may be carried out by dry granulation, wet granulation, melt granulation, fluidized bed granulation, direct compression, molding and compression molding. Preferably it may be carried out by the method of dry granules, wet granules, melt granules. For example, when prepared by a direct tableting method, it can be formulated orally by mixing with acebrophylline, a pharmaceutically acceptable additive and then tableting and coating.
- acebrophylline when prepared by the compressed granulation method, it can be prepared by mixing with acebrophylline, a pharmaceutically acceptable additive, and then granulating the granulated granules with a compressed granule, then tableting and coating.
- acebrophylline when prepared by the wet granulation method, acebrophylline may be prepared by mixing the acebrophylline with a pharmaceutically acceptable additive and then preparing the wet granules in a binder solution, followed by drying and sieving, followed by tableting and coating.
- the acebrophylline-containing preparation according to the present invention is not only administered orally to give an immediate therapeutic effect, but also to maintain a constant concentration of active ingredients in plasma for a considerable time, and to reduce the number of administrations once a day. In addition, it is very useful because it can increase the drug conformity to the patients as a result can increase the dosing degree.
- the present invention provides a method for imparting early rapid and late sustained release to acebrophylline pharmaceutical composition comprising adding and mixing a hydrophobic sustained release base to a pharmaceutical composition comprising acebrophylline. to provide.
- the term "initial immediate release” means a case in which the dissolution rate of acebrophylline at a time point of 1 hour in a pH 1.2 eluate is 20-52 weight 3 ⁇ 4> when analyzing the dissolution rate according to the paddle method described above, or the pharmaceutical composition (E.g., oral administration) to the human body (e.g., oral administration), e.g., 2-4.5 hours, 2-4 hours, 2.5-4 hours or 3-4 hours after administration It is meant that the drug is released rapidly (eg, exhibits the maximum blood concentration) at the time point.
- the term "late sustained release” means a sustained release following the elution of acebrophylline by the initial rapid release described above.
- the pharmaceutical composition of the present invention may be subjected to initial immediate release, followed by a rapid decrease in release rate followed by sustained release at a reduced release rate.
- the pharmaceutical composition of the present invention may be sustained release at such a reduced release rate, with an initial immediate release followed by a slow release rate.
- the method of the present invention can be carried out in various ways.
- the process of the present invention comprises the steps of (a) mixing (optionally adding glidants) to acebrophylline as an active ingredient and optionally adding a lubricant; ; And (b) adding and mixing hydrophobic sustained release bases and excipients that can impart initial immediate and late sustained release to the product of step (a), and optionally (optionally, add glidants) to tableting. It can be implemented by the process of including. Optionally, tablets prepared after tableting may be coated.
- the hydrophobic sustained-release-based pharmaceutical composition is a dissolution rate of acebrophylline SO-52% by weight at 1 hour after dissolution, acebrophylline at 6 hours after dissolution The dissolution rate of 75-100 weight? 3 ⁇ 4.
- the hydrophobic sustained-release agent used in the present invention is acetyltributyl citrate, carnauba wax, cel lulose acetate, glycerin monostearate (glycerin monostearate), glyceryl monooleate, glyceryl palmitostearate, hydrogenated castor oil, polyoxyglycerides, stearic acid ), Tributyl citrate, pewter wax, yel low wax, zein, cel lulose acetate phthalate, acetyl alcohol , Acetyl esters wax, dibutyl sebacate, ethylcel lulose, glyceryl behenate, hydrogenated vegetable oil type Khydrogenated vegetable oil type I At least one member selected from the group consisting of i sopropyl palmitate, polymethacrylates, shellac, stearyl alcohol, and combinations thereof.
- the pharmaceutical composition mixed with the hydrophobic sustained-release agent is provided in the form of a solid oral preparation.
- the pharmaceutical composition in which the hydrophobic sustained-release base is mixed is provided in the form of a single matrix tablet.
- the pharmaceutical composition mixed with the hydrophobic sustained-release agent shows immediate release by showing the maximum blood concentration of ambroxol at 2-4.5 hours after oral administration to the human body once a day. It shows sustained release.
- the pharmaceutical composition containing the hydrophobic sustained-release agent is a maximum blood concentration of Ambtoxol 90-250 ng / mL when orally administered 200 mg acebrophylline once a day in the human body to be.
- the pharmaceutical composition mixed with the hydrophobic sustained-release agent is AUC ( 0 -36 hr) for the amphotoxol in the blood when orally administered 200 mg acebrophylline once a day in the human body
- the value is 1600-2, 700 ng hr / mL.
- the acebrophylline-containing ' single matrix sustained-release preparation provided according to the present invention can ensure a superior therapeutic effect by taking a single dose per day by designing the preparation so that the manufacturing process is simple but simultaneously exhibits rapid efficacy and sustained release. Increasing the convenience of taking the drug can be expected to significantly improve the medication homility and treatment effect.
- Figure 1 shows the dissolution test results of the formulation prepared according to Example 1-4, Example 2-4 and Comparative Example 1.
- Figure 2 shows the results of in vivo human PK (pharmacokinetics) experiments of commercially available sulfolase capsules and the preparations prepared according to Comparative Example 1.
- Figure 3 shows the results of in vivo human PK experiments of commercially available sulfolase capsules and the preparations prepared according to Examples 1-4.
- Figure 4 shows the results of in vivo human PK experiments of commercially available sulfolase capsules and the preparations prepared according to Examples 2-4.
- the components 1 to 4 of Table 1 were respectively mixed and granulated.
- the granulated granules were added with the ingredients of 5 to 7 in Table 1 to mix and tablet. After tableting, the coating was carried out using a coating agent of 8.
- Example 1 Example 1 Example 1 Example 1-2 Example 1-3 Example 1-4
- the components 1 to 4 of Table 2 were respectively mixed and granulated.
- the granulated granules were added with the ingredients of 5 to 6 in Table 2 to mix and tablet. After tableting, the coating was carried out using a coating agent of 7.
- Example 3 Preparation of Hydrophobic Sustained-Release Formulations Containing Glyceryl Monobehenate
- the components 1-4 of Table 3 were combined and granulated, respectively.
- the granulated granules were added with the ingredients of 5 to 6 in Table 3 to mix and tablet. After tableting, the coating was carried out using a coating agent of 7.
- the components 1 to 3 of Table 4 were respectively mixed and granulated.
- the granulated granules were added with the ingredients of 4 to 6 in Table 4 to mix and tablet. After tableting, the coating was carried out using a coating agent of 7.
- the sustained-release layer was mixed with the composition shown in Table 5, and compressed using a ler compactor to form dry granules.
- the immediate layer was mixed with the composition of Table 5 to form granules.
- the prepared granules of the sustained release layer and the immediate release layer were compressed into double tablets. After tableting, the coating base of Table 5 (Opadry) was used to coat 6% of the weight of the double tablet. [Table 5]
- Examples 1-4 For the formulations of Examples 2-4 and Comparative Example 1, respectively, at 500 mL of pH 1.2 eluate (1 solution in the Korean Pharmacopoeia Elution Test) using the paddle method, The dissolution test was initiated at 37 ⁇ 0.5 ° C. and 50 rpm. When the elution test was started for 2 hours, 400 mL of the test solution 2C0.235M anhydrous sodium hydrogen phosphate (Na 2 HP0 4 anhydrous) was carefully added to the pH 1.2 eluent to prepare a pH 6.8 solution, and then the dissolution test was continued. The eluate was taken at the specified elution time, and the concentration of acebrophylline was confirmed by HPLC and the elution rate was analyzed. The dissolution rate test results over time are shown in FIG. 1.
- Examples 2-4, 3, and 4 which are the formulations of the present invention, have similar initial dissolution rates (dissolution rates at 1 hour dissolution), as well as dissolution rates of 35 %, 41% and 37%), it was found to elute better than Comparative Example 1 including the slow release layer over time.
- the elution rates at the 6 hour elution points of Comparative Examples 1, 2-4, 3 and 4 were 65%, 82%, 80% and 78%, respectively.
- the pharmaceutical composition of the present invention exhibits a fast medicinal effect with superior initial dissolution rate compared to the rapid release of the comparative example, and is superior to the dissolution rate of the sustained release layer of the comparative example even after a time, and thus can be taken once a day, thereby increasing the convenience of taking the drug simultaneously. It can be seen that the improved therapeutic effect can be expected.
- Experimental Example 2 Comparison of in vivo human PK (Sulfolase capsule and Comparative Example 1)
- a solution of sildenafil citrate (10 ug / mL in 50%) is used as an internal standard.
- methanol 10 mL and 100 mL of 0.05M NaOH solution were added and vortex mixed for 5 seconds.
- 2 mL of extraction solvent methyl tert-butyl ether was added thereto, followed by vortexing for 2 minutes, followed by centrifugation at 4,000 rpm for 5 minutes.
- Example 1-4 preparation according to the present invention had a similar concentration of ambroxol in blood than commercially available sulfolase capsules which should be taken twice a day with only one dose. Through this, it was proved that once-daily administration can increase the convenience of taking : and further improve the therapeutic effect. .
- the formulation of Example 1-4 reached the initial concentration of about 215 ng / mL at 3 hours of administration, and showed early rapid release, followed by sustained release, which is almost consistent with the dissolution rate experiment of Experimental Example 1. Is the result.
- Experimental Example 4 in vivo human PK experiment (sulforase capsules and Example 2-4)
- Example 2-4 the formulation of Example 2-4 according to the present invention may be used only once. It was confirmed that blood ambroxol concentrations were similar to those of commercial sulfolase capsules that should be taken twice. Through this, it was proved that once-daily dosing can increase the convenience of taking and further improve the therapeutic effect. In addition, the formulation of Example 2-4 reached the initial concentration of about 95 ng / mL blood at 4.5 hours of administration and showed early rapid release and then sustained release, which is almost consistent with the dissolution rate experiment of Experimental Example 1. The result is.
Abstract
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14875660.4A EP3087979A4 (en) | 2013-12-26 | 2014-12-19 | Sustained-release pharmaceutical composition containing acebrophylline and hydrophobic sustained-release agent |
JP2016536820A JP2016539171A (ja) | 2013-12-26 | 2014-12-19 | アセブロフィリン及び疎水性徐放性基剤を含む徐放性薬学組成物 |
CN201480067019.6A CN105828808B (zh) | 2013-12-26 | 2014-12-19 | 包含溴醋茶碱及疏水性缓释剂的缓释型药学组合物 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020130164670A KR101506626B1 (ko) | 2013-12-26 | 2013-12-26 | 아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 |
KR10-2013-0164670 | 2013-12-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2015099364A1 true WO2015099364A1 (ko) | 2015-07-02 |
Family
ID=53028780
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2014/012602 WO2015099364A1 (ko) | 2013-12-26 | 2014-12-19 | 아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP3087979A4 (ko) |
JP (1) | JP2016539171A (ko) |
KR (1) | KR101506626B1 (ko) |
CN (1) | CN105828808B (ko) |
WO (1) | WO2015099364A1 (ko) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN111202716B (zh) * | 2018-11-05 | 2021-10-26 | 广州白云山光华制药股份有限公司 | 茶碱缓释片及其制备方法 |
CN115212173A (zh) * | 2022-07-11 | 2022-10-21 | 上海现代药物制剂工程研究中心有限公司 | 一种盐酸氨溴索球形缓释微粒、制备方法及用途 |
CN116803378B (zh) * | 2023-08-24 | 2023-11-17 | 北京福元医药股份有限公司 | 一种格列齐特缓释片剂及其制备方法 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040077244A (ko) * | 2003-02-28 | 2004-09-04 | 한국유나이티드제약 주식회사 | 제어방출형 경구 펠렛제제 및 그 제조방법 |
KR20070045940A (ko) * | 2005-10-27 | 2007-05-02 | 주식회사종근당 | 서방출과 pH 의존성 속방출을 나타내는 약제학적 조성물 |
JP2008201706A (ja) * | 2007-02-20 | 2008-09-04 | Kowa Pharmaceutical Co Ltd | 小型徐放性錠剤 |
KR20120033557A (ko) * | 2010-09-30 | 2012-04-09 | 현대약품 주식회사 | 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3530761A1 (de) * | 1985-08-28 | 1987-03-05 | Klinge Co Chem Pharm Fab | Arzneimittelkombination mit synergistischer wirkung |
CN1810237A (zh) * | 2005-01-28 | 2006-08-02 | 天津药物研究院 | 一种氨溴索盐类缓释片及其制备方法 |
CN101352419B (zh) * | 2007-07-26 | 2010-08-11 | 天津药物研究院 | 一种醋溴茶碱无糖型颗粒剂及其制备方法 |
-
2013
- 2013-12-26 KR KR1020130164670A patent/KR101506626B1/ko active IP Right Grant
-
2014
- 2014-12-19 JP JP2016536820A patent/JP2016539171A/ja active Pending
- 2014-12-19 CN CN201480067019.6A patent/CN105828808B/zh active Active
- 2014-12-19 EP EP14875660.4A patent/EP3087979A4/en active Pending
- 2014-12-19 WO PCT/KR2014/012602 patent/WO2015099364A1/ko active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20040077244A (ko) * | 2003-02-28 | 2004-09-04 | 한국유나이티드제약 주식회사 | 제어방출형 경구 펠렛제제 및 그 제조방법 |
KR20070045940A (ko) * | 2005-10-27 | 2007-05-02 | 주식회사종근당 | 서방출과 pH 의존성 속방출을 나타내는 약제학적 조성물 |
JP2008201706A (ja) * | 2007-02-20 | 2008-09-04 | Kowa Pharmaceutical Co Ltd | 小型徐放性錠剤 |
KR20120033557A (ko) * | 2010-09-30 | 2012-04-09 | 현대약품 주식회사 | 레보드로프로피진을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 |
Non-Patent Citations (1)
Title |
---|
See also references of EP3087979A4 * |
Also Published As
Publication number | Publication date |
---|---|
KR101506626B1 (ko) | 2015-03-30 |
CN105828808A (zh) | 2016-08-03 |
CN105828808B (zh) | 2020-03-13 |
JP2016539171A (ja) | 2016-12-15 |
EP3087979A1 (en) | 2016-11-02 |
EP3087979A4 (en) | 2017-07-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101834033B1 (ko) | 주의력 결핍 장애 치료용 고체 경구 제약 조성물 | |
EP3556369B1 (en) | Olaparib oral sustained and controlled release pharmaceutical composition and uses thereof | |
KR101774676B1 (ko) | 히드로모르폰 및 날록손을 포함하는 제약 조성물 | |
WO2009034541A2 (en) | Controlled release pharmaceutical dosage forms of trimetazidine | |
HRP20040323A2 (en) | Oral dosage form for propiverine or its pharmaceutically acceptable salts with an extended release of the active ingredient | |
NZ201008A (en) | Oral preparations containing dipyridamole and at least 5 molar equivalents of orally acceptable acidic excipient | |
TW200822925A (en) | Amlodipine-contained particle and orally disintegrating tablet | |
KR20090029830A (ko) | 소장 내에서 활성성분의 방출이 제어되는 경구투여용 약제학적 조제물 및 그의 제조방법 | |
WO2014209087A1 (en) | Pharmaceutical capsule composite formulation comprising tadalafil and tamsulosin | |
KR102078805B1 (ko) | 토파시티닙을 포함하는 약제학적 조성물 | |
US20100256088A1 (en) | Low dose therapy for treating viral infections | |
WO1997033574A1 (fr) | Comprimes a liberation prolongee a base de valproate metallique | |
WO2015099364A1 (ko) | 아세브로필린 및 소수성 서방기제를 포함하는 서방형 약학 조성물 | |
KR20070044911A (ko) | 염산 탐스로신 함유 방출조절 제제 | |
ES2860694T3 (es) | Composición farmacéutica de liberación sostenida que contiene rivastigmina | |
KR20140001357A (ko) | 아세브로필린을 포함하는 속효성과 지속성을 동시에 갖는 약제학적 조성물 | |
EP3251661A1 (en) | Raloxifene sprinkle composition | |
US7820200B2 (en) | Pharmaceutical composition for the sustained release of hydralazine and use thereof as a support for cancer treatment | |
KR101506627B1 (ko) | 아세브로필린 및 친수성 서방기제를 포함하는 서방형 약학 조성물 | |
TWI589292B (zh) | 用於控管噁心及嘔吐之組合物 | |
JP2020189815A (ja) | デュロキセチン製剤およびその安定化方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14875660 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 2016536820 Country of ref document: JP Kind code of ref document: A |
|
REEP | Request for entry into the european phase |
Ref document number: 2014875660 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2014875660 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: DE |